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Abstract 
 
Background: The effect of triptolide (TPL) on cardiac fibroblasts (CFbs) and cardiac fibrosis remain unknown till now. 
This study was conducted to explore the effects of TPL on proliferation and apoptosis of angiotensin II (Ang 
II)-induced CFbs.  
Materials and Methods: Ang II was used to promote proliferation of CFbs. Two dosages of TPL (10ng/ml and 
100ng/ml) were chosen. MTT assay was used to detect cell survival rate in vitro. Flow cytometer was performed to 
analyze apoptosis of CFbs. Hydroxyproline concentration was detected with hydroxyproline assay kit. Quantitative 
real-time PCR was used to detect the expression of TGF-β1 and Smad3 mRNA.  
Results: Ang II promoted CFbs proliferation significantly. Compared to Ang II group, TPL markedly reduced the 
viability of CFbs and its Hydroxyproline concentration (P<0.05). Besides, TPL can significantly promote apoptosis of 
CFbs (P<0.05). Furthermore, TPL reduced the expressions of TGF-β1 and Smad3 mRNA in Ang II-induced CFbs 
(P<0.05).  
Conclusion: TPL can inhibit the proliferation of CFbs in rats by down-regulating TGF-β1/Smad3 signaling pathway. 
TPL might be a promising therapeutic drug for myocardial fibrosis. 
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Introduction 
 
Cardiac fibroblasts (CFbs), the highest cell population in the myocardium, play major roles in maintaining normal 
cardiac structure and function (Goldsmith et al., 2014). CFbs are of utmost importance for the pathogenesis of 
myocardial fibrosis. CFbs promote cardiac repair by controlling the synthesis and degradation of extracellular matrix 
(Dixon and Cunnington, 2011; Goldsmith et al., 2014). In the pathological status, some mechanical and chemical 
stimuli may promote the migration, proliferation and differentiation of CFbs, which may secrete excess amount of 
collagen fibers. As a result, cardiac fibrosis or myocardial scarring occurs and progresses gradually.  
Myocardial fibrosis has already become one of the most difficult stages in the treatment of chronic heart failure 
(CHF) hence has prognostic relevance. Thus, how to ameliorate myocardial fibrosis is a current research topic in the 
field of CHF (Heymans et al., 2015). The mechanisms of CHF are diverse and complex (Yancy et al., 2013). Among 
the risk factors, immune-inflammatory activation was reported to be a cornerstone in the development and progression 
of myocardial fibrosis and CHF. Therefore, anti-inflammatory and immunomodulation therapy has been widely studied 
around the world and might be a promising strategy for the treatment of CHF in the future (Liu et al., 2015; Nymo et al., 
2014). 
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Triptolide (TPL) is a diterpene triepoxide extracted from Tripterygium wilfordii Hook F, which has already been 
used in Traditional Chinese Medicine for thousands of years to treat immune-related diseases. It’s a monomeric 
compound and has been reported to have immunosuppressive and anti-inflammatory properties (Li et al., 2014; Liu et 
al., 2015). Leonard et al. found that TPL can inhibit accumulation of inflammatory cells and may have therapeutic 
benefits for patients with obliterate airway disease (Leonard et al., 2002). However, whether TPL can inhibit the 
proliferation of CFbs and attenuate myocardial fibrosis in CHF rats are still uncertain. We hypothesized that TPL, as an 
immunosuppressive agent, could reverse myocardial fibrosis and inhibit CFbs proliferation in CHF rats. 
Therefore, a series of experiments in vivo and in vitro were conducted to evaluate the effects of TPL on 
myocardial fibrosis in rats and on proliferation of CFbs in neonatal rats. In our previous study, we have demonstrated 
TPL significantly attenuated myocardial fibrosis and improved cardiac function through suppressing several signaling 
pathways in isoprenaline-induced cardiac remodeling rats (Liu et al., 2015). In this study, we assessed the effects of 
TPL on proliferation and apoptosis of angiotensin II (Ang II)-induced CFbs. This study revealed the effects of TPL on 
myocardial fibrosis at the cellular level. 
 
Materials and methods 
Chemicals and reagents 
 
TPL (C20H24O6, purity>98% by HPLC) was obtained from Gold Wheat Biotech Co., Ltd. (Shanghai, China). Ang 
II (C50H71N13O12, purity>98.0% by HPLC) was purchased from Meilun Biotech Co., Ltd. (Dalian, China). Dulbecco's 
modified eagle medium/Nutrient mixture F-12 (DMEM/F-12, 1:1) was purchased from Hyclone (Utah, USA). TPL was 
dissolved in dimethyl sulfoxide (DMSO), which was obtained from Hyclone (Utah, USA). 
Methylthiazolyldiphenyl-tetrazolium bromide assay kit (MTT), Annexin V-FITC apoptosis kit and hydroxyproline 
(HYP) testing kit were purchased from Nanjing Jiancheng Bioengineering Institute (Nanjing, China). TRIzol 
(Invitrogen, CA, USA), All-in-One TM first strand cDNA synthesis kit and All-in-One TM quantitative real-time 
polymerase chain reaction (PCR) mix (SYBR Green Method, GeneCopoeia, MD, USA) were also used. CO2 incubator 
(HERAEUS, BB15, USA), quantitative real-time PCR (EPPENDORF, Mastercycler ep realplex2, Germany) and flow 
cytometer (BECKMAN COULTER, COULTER EPICS XL, USA) were used. 
  
Culture of rat CFbs 
 
Primary CFbs of neonatal Wistar rats were obtained from Jiangyin CHI Scientific, Inc. (Jiangyin, China). The 
product number and verification number are No.66160-232 and No.20140520HXM. The primary CFbs were cultured 
in DMEM/F-12(1:1) containing 10% fetal bovine serum under a humidified atmosphere of 5% CO2 at 37℃. The 
nutrient medium was changed every 48 hrs. When the cells coated the bottom of the bottle, they will be sub-cultured in 
new culture dishes. The second and third generations of CFbs were chosen to use in this study. 
 
Grouping and interventions   
 
There were four groups set in this study: control (Con), Ang II (Ang), low-dose triptolide (LT) and high-dose 
triptolide group (HT). Con group was cultured in DMEM/F-12(1:1) only. Ang group was cultured in DMEM/F-12(1:1) 
with Ang II (10-7 mol/L). LT group was cultured in DMEM/F-12(1:1) with Ang II (10-7 mol/L) and TPL (10 ng/ml). HT 
group was cultured in DMEM/F-12(1:1) with Ang II (10-7 mol/L) and TPL (100 ng/ml). The CFbs in these groups were 
all incubated under a humidified atmosphere of 5% CO2 at 37℃ for 48 hours. 
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MTT assay   
 
The viabilities of rat CFbs in different groups were calculated to evaluate the proliferation activity in vitro by 
using the MTT assay. The rat CFbs were harvested and seeded with a rate of 2000 cells per each hole of the 96-well 
plates at a density of 2×104 /mL during the logarithmic growth phase. They were cultured in DMEM/F-12(1:1) with 
10% fetal calf serum under a humidified atmosphere of 5% CO2 at 37℃ for 24 hours. Then, different dosages of drugs 
were given. The CFbs were further cultured in DMEM/F-12(1:1) with 1% fetal calf serum under the same circumstance. 
According to the instruction of MTT assay kit, 50μl of 1×MTT solution was added to each well. The CFbs were 
incubated in DMEM/F-12(1:1) with 1% fetal calf serum for an additional four hours. Then, 150μl DMSO was used to 
dissolve the MTT-formazan crystals. The optical density (OD) (λ = 630 nm) was obtained by using a microplate reader.  
The corrected ODs were calculated by subtracting the OD of empty well. At last, the viability in each group was 
calculated according to the following equation: Viability = (Corrected OD of treated group/ Corrected OD of control 
group) × 100%. 
 
HYP concentration   
 
The rat CFbs were seeded in each well of the 24-well plates at a density of 5×105 /mL during the logarithmic 
growth phase. They were cultured in under a humidified atmosphere of 5% CO2 at 37℃ for 24 hours. Then, different 
dosages of drugs were given. Finally, the CFbs were incubated in DMEM/F-12(1:1) with 1% fetal calf serum for an 
additional 72 hrs. The rat CFbs were harvested and the concentration of HYP was detected according to the assay kit 
provided by Nanjing Jiancheng Bioengineering Institute (Nanjing, China).  
 
Flow cytometer 
 
Different dosages of drugs were added in each well when the CFbs were in logarithmic growth phase. After an 
additional 72 hrs incubation, the cells were harvested. Then, Annexinn V-FITC 5μl and PI 5μl were added in the tube 
for 10 min in a condition away from light. At last, the apoptotic CFbs were identified by flow cytometer and apoptotic 
rates were calculated by CXP 2.0 software. 
 
Real-time PCR 
 
Total RNA was extracted from CFbs by TRIzol reagent and reverse transcribed to cDNA by the All-in-One TM 
first strand cDNA synthesis kit. Two microliter cDNA were amplified by quantitative real-time PCR using the 
All-in-One TM quantitative real-time PCR mix. Beta-actin was used as an internal control gene to normalize the 
mRNA levels of transforming growth factor-β1 (TGF-β1) and drosophila mothers against decapentaplegic proteins-3 
(Smad3). The sequences used in this study were as follows: TGF-β1(F) 5’-TGCTTCAGCTCCACAGAGAA-3’, 
TGF-β1(R) 5’-TGGTTGTAGAGGGCAAGGAC-3’, Smad3(F) 5’-GGCAGGATGTTTCCAGCTA-3’,Smad3(R) 
5’-GCAGTCC ACAGACCATGTCA-3’, β-actin(F) 5’-AGGGAAATCGTGCGTGACAT-3’, β-actin (R) 
5’-GAACCGCTCATTGCCGATAG-3’. Each experiment was performed at least three times.  
 
Statistical analysis  
 
IBM SPSS software Version 20.0 for Windows (SPSS Inc., Chicago, USA) was used for the data analysis. The 
data were presented as mean ± standard deviation. Normality tests and homogeneity of variance tests were performed. 
One way ANOVA followed by LSD tests was used in the multiple comparisons of quantitative data. While 
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Kruskal-Wallis test was performed if non-normal distribution or heterogeneity of variance was found. A two-tale 
P<0.05 was considered to indicate a significant difference (Liu et al., 2015). 
 
Results 
Effects of TPL and Ang on proliferation of rat CFbs 
   
The cultured CFbs in Con group were typical fibroblast morphology which were spindle-shaped or irregular 
triangle. The CFbs distributed evenly and tightly on the culture flask. In Ang group, the CFbs proliferated significantly, 
arranged closely and were in the shape of fusiform or square. The numbers of CFbs decreased markedly after the 
treatment of TPL. There were a few scattered dead cells in the culture flask (Fig.1). 
 
 
 
 
Figure 1:  Morphological features of the CFbs in different groups (100×). 
 
The cultured cells in Con group were typical fibroblast morphology and distributed evenly and tightly (A). The CFbs in 
Ang group proliferated significantly and were in the shape of fusiform or square (B). In the LT (C) and HT group (D), 
the numbers of CFbs were decreased markedly, especially in the HT group. Con=control; Ang=Angiotensin II; 
LT=low-dose triptolide; HT=high-dose triptolide group. 
Effect of TPL on viability of rat CFbs  
 
 The viability of CFbs in Ang group was significantly higher than that of Con group (P=0.001). Compared to Ang 
group, the viability of CFbs was markedly reduced in HT group (3.24±1.58 vs. 1.23±0.34, P=0.006). No significant 
differences of viabilities were found between LT and Ang group (Fig.2). 
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Figure 2: Effect of TPL on viability of CFbs (n=8).  
Compared to Ang group, the viabilities of CFbs in LT and HT group decreased significantly. Con=control; 
Ang=Angiotensin II; LT=low-dose triptolide; HT=high-dose triptolide group.  
* P<0.05 vs. Con; # P<0.05 vs. Ang 
 Effect of TPL on HYP concentration in rat CFbs  
 
 The HYP concentration in Ang group was significantly higher than that of Con group (1.43±0.54 vs. 0.40±0.29, 
P=0.007). The HYP concentration in HT group was lower than that of Ang group (0.59±0.20 vs. 1.43±0.54, P=0.019) 
and LT group (0.59±0.20 vs. 1.27±0.30, P=0.047). No marked differences in the HYP concentration between LT and 
Ang group were found (Fig.3). 
 
Figure 3: Effect of TPL on HYP concentration in CFbs (n=3). 
Compared to Con group, Ang may increase the collagen concentration in CFbs. Compared to Ang group, the collagen 
concentrations in LT and HT group decreased significantly. HYP=hydroxyproline; Con=control; Ang=Angiotensin II; 
LT=low-dose triptolide; HT=high-dose triptolide group.  
*P<0.05 vs. Con; #P<0.05 vs. Ang 
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Effect of TPL on apoptosis of rat CFbs 
 
As shown in Fig.4, there was no noticeable difference in the apoptosis rate of CFbs between Ang and Con group 
(1.14±0.52 vs. 1.09±0.55, P>0.05). Compared to Ang group, the apoptosis rates of CFbs in LT group (3.00±0.68 vs. 
1.14±0.52, P=0.012) and HT group (5.29±0.97 vs. 1.14±0.52, P<0.001) were significantly increased. Moreover, the 
apoptosis rate was higher in HT group than that of LT group P=0.004). 
 
Figure 4: Effect of TPL on apoptosis of CFbs (n=3).  
Compared to Ang group, TPL treatment significantly promoted apoptosis of CFbs, especially in HT group. A=Con 
(control); B=Ang (Angiotensin II); C=LT (low-dose triptolide); D=HT (high-dose triptolide group). *P<0.05 vs. Con; 
#P<0.05 vs. Ang 
 
TPL down-regulates TGF-β1/Smad3 signaling in rat CFbs 
 
As shown in Fig.5, In the HT group, the expressions of TGF-β1 mRNA (0.66±0.15 vs. 1.36±0.12, P<0.001) and Smad3 
mRNA (0.25±0.10 vs. 1.53±0.14, P=0.022) were significantly lower than those of Ang group. Also, compared to Ang 
group, the expression of TGF-β1 mRNA was reduced in LT group (0.74±0.09 vs. 1.36±0.12, P=0.001). There was no 
statistical difference in the comparison of expressions of Smad3 mRNA between LT and Ang group (P>0.05).  
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Figure 5: Effect of TPL on TGF-β1/Smad3 signaling in CFbs (n=3). 
Compared to Ang group, the expressions of TGF-β1 mRNA reduced in HT and LT group. The expression of Smad3 
mRNA significantly reduced in HT group. TGF-β1=transforming growth factor-β1; Smad3=drosophila mothers against 
decapentaplegic proteins-3; Con=control; Ang=Angiotensin II; LT=low-dose triptolide; HT=high-dose triptolide group.  
*P<0.05 vs. Con; #P<0.05 vs. Ang 
Discussion 
 
In this study, we evaluated the effects of TPL on proliferation and apoptosis of Ang II-induced rat CFbs in vitro. 
Ang II can induce proliferation and increase the HYP concentration of CFbs significantly. TPL inhibited the Ang 
II-induced proliferation of CFbs from neonatal rats. Compared to Ang group, TPL markedly reduced the viability of 
CFbs in a dose dependent trend and the number of CFbs decreased markedly after the treatment of TPL. Besides, we 
firstly found that TPL can promote apoptosis of Ang II-induced CFbs, which may be an important mechanism of its 
antifibrotic effect to myocardial fibrosis in CHF rats. Moreover, TPL can also attenuate pro-fibrotic signaling in CFbs. 
Compared to Ang group, the HYP concentration and expressions of TGF-β1 mRNA and Smad3 mRNA were 
significantly lower in TPL treated CFbs. It is also the first report concerning the effect of TPL on TGF-β1/Smad3 
pathway in CFbs. 
It has been well known that Ang II is one of the most important vasoactive peptide in the 
renin-angiotensin-aldosterone system (Velez et al., 2012). When Ang II binds with its specific receptor, it can promote 
the secretion of aldosterone and cause water-sodium retention, which are essential in the development of myocardial 
fibrosis, hypertension and CHF. Ang II can also promote proliferation and differentiation of CFbs, increase the 
synthesis and excretion of fibrotic factors and collagens, resulting in the occurrence and progress of myocardial fibrosis 
(Yamazaki et al., 2012). Therefore, Ang II is often used to introduce CFbs proliferation in relevant cell experiments, 
including our present study. 
TPL is a diterpene triepoxide and its molecular formula C20H24O6. TPL is a monomeric compound extracted from 
a traditional Chinese herb Tripterygium wilfordii Hook F (Liu et al., 2015). It has been proved to have significant 
immunosuppressive and anti-inflammatory properties (Chen et al., 2015; Liu et al., 2015; Zhang et al., 2009). 
Tripterygium wilfordii was effective in halting the progress of graft coronary arteriosclerosis by inhibiting of the 
PDGF-A chain mRNA in cardiac graft (Hachida et al., 1999). It can also improve cardiac function and quality of life in 
rheumatoid arthritis patients by increasing peripheral blood B and T lymphocyte attenuator expression of CD19+ and 
CD24+ B cells and reducing B cell-mediated abnormal humoral immunity and oxidative stress damage  (Cao et al., 
2011; Sun et al., 2015). As for cell experiments, Lu et al. (Lu et al., 2008) found that TPL effectively reduced the 
expression of IL-18 at protein and gene levels and inhibited the bioactivity of IL-18 and nuclear factor-κB in 
rheumatoid arthritis synovial fibroblasts. But the effects of TPL on CFbs were barely reported. To the best of our 
knowledge, only Xu et al (Xu et al., 2008) had reported that TPL reduced the CFbs proliferation and the synthesis of 
pro α1 (I) collagen in a dose-dependent way (Xu et al., 2008). Then they drew a conclusion that TPL might attenuate 
myocardial fibrosis through inhibiting the proliferation and collagen synthesis of CFbs. However, the evidence is 
insufficient to support this conclusion because no animal experiment has been conducted. As is well known today, 
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TGF-β1/Smad3 signaling pathway is one of the dominant pathways in fibrosis (Wang et al., 2013). TGF-β1 has been 
considered as an attractive therapeutic target in the treatment of fibrotic diseases (Lee et al., 2014). The activation of 
this pathway may promote CFbs differentiation, increase the extracellular matrix protein deposition and connective 
tissue growth factor production (Liu et al., 2015; Zhang et al., 2013). However, these factors were not detected in Xu’s 
study. 
Therefore, based on the experience of previous studies, some improvements and complements were achieved. In 
our animal experiment, TPL has shown its antifibrotic effect in isoprenaline-induced CHF and cardiac fibrosis rats (Liu 
et al., 2015). In this in vitro study, the expressions of TGF-β1 and Smad3 mRNA of CFbs were significantly reduced by 
TPL, indicating that TPL may affect cardiac fibrosis via down-regulating TGF-β1/Smad3 signaling. Besides, we also 
found that TPL can inhibit the proliferation and reduce the HYP concentration in Ang II-induced CFbs, which were 
similar to the previous report (Xu et al., 2008). Furthermore, the pro-apoptic effect of TPL has been reported in 
lymphoblastic leukemia cells, cardiomyocytes and airway smooth muscle cells (Chen et al., 2015; Zhou et al., 2015). In 
this study, the effect of TPL on CFbs apoptosis was firstly determined. The results indicated that TPL can promote 
apoptosis of Ang II-induced CFbs in a dose dependent way, which might also play an important role in the antifibrotic 
effect of TPL in the treatment of myocardial fibrosis. There are some limitations of our study. Firstly, this is a basic 
research. The results and conclusions cannot be expanded to the clinical aspects relating human beings. TPL cannot be 
prescribed for the CHF patients yet. Further clinical trials are needed. Secondly, the number of tested groups was rather 
small. Only two different dosages were set in this study. And there was only one intervention-time point (48 h) set in 
this study because it’s a preliminary experiment. Besides, no inflammatory factors and apoptosis-related proteins were 
included in this experiment. Therefore, we will test more intervention groups and detect more indexes in the following 
studies.  
In conclusion, TPL can inhibit proliferation, promote apoptosis and reduce the expressions of TGF-β1 and Smad3 
mRNA in Ang II-induced CFbs. TPL might be a promising therapeutic drug for myocardial fibrosis. Further studies are 
needed to explore the potential mechanism and clinical efficiency before it is widely used in CHF patients.  
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